CD19 and lymphoma: The primary goal of these allogeneic CD19 CAR–T cells is to evaluate the feasibility, safety, andin vivo persistence of UCART019 adoptively transferred T cells in patients with relapsed or refractory CD19+ leukemia and lymphoma.